Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement

View Full Paper
Ask AI
Bookmark
Share

Authors

VSVedant ShahDPDeevyashali ParekhSESafa Elzein

Discussion

Loading...

Member takes

Overview

Real-world analysis shows no significant difference in overall survival between BTKi monotherapy and fixed-duration BTKi-venetoclax in CLL, suggesting equal efficacy.

Key Points

  • This analysis indicates no significant difference in overall survival for patients receiving BTKi or BTKi-venetoclax treatment for CLL.
  • The median follow-up was 730 days for the monotherapy group and 606 days for the combination therapy group.
  • Propensity score matching was employed to ensure balanced baseline characteristics between the two treatment cohorts.
  • The safety profiles for both treatments were similar, with no clinically significant differences noted between the groups.

Cite This Study

Shah et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6c1https://doi.org/10.1182/blood-2025-7435
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes with a fixed duration combination of bruton tyrosine kinase inhibitors and venetoclax in chronic lymphocytic leukemia: A systematic review and meta-analysis2025
  2. 2Long-term outcomes in high-risk patients with chronic lymphocytic leukemia treated with targeted therapies in the real-world2025
  3. 3Upfront continuous BTK inhibitor (BTKi) versus time-limited venetoclax-BTKi combinations in CLL across IGHV subgroups: Results of an indirect analysis2025
  4. 4Efficacy of fixed-duration venetoclax-based regimens as first-line in chronic lymphocytic leukemia: A systematic review and meta-analysis of clinical trials2025
  5. 5Real‑world effectiveness and patient-centered outcomes of fixed‑duration vs continuous first‑line therapy in chronic lymphocytic leukemia (CLL)2025